Table 1.
Patient cohort characteristics
| Characteristic | Cohort 1: TNBC untreated (n = 66) | Cohort 2: TNBC treated (n = 78) |
|---|---|---|
| Age (years) | ||
| <50 | 15 (23) | 33 (42) |
| ≥50 | 51 (77) | 45 (58) |
| T stage | ||
| T1 (<2.0 cm) | 36 (55) | 33 (42) |
| T2 (2–5cm) | 23 (35) | 40 (51) |
| T3 (>5 cm) | 3 (5) | 5 (6) |
| TX | 4 (6) | 0 (0) |
| Lymph node stage | ||
| NO | 35 (53) | 45 (58) |
| N1 | 17 (26) | 14 (18) |
| N+ | 14 (21) | 19 (24) |
| Grading | ||
| G1 | 8 (12) | 0 (0) |
| G2 | 41 (62) | 6 (8) |
| G3/G4 | 17 (26) | 54 (69) |
| GX | 0 (0) | 18 (23) |
| Histology | ||
| Ductal | 36 (55) | 56 (72) |
| Other | 30 (45) | 22 (28) |
| Radiotherapy | ||
| Yes | 35 (53) | 74 (95) |
| No | 31 (47) | 4 (5) |
| Endocrine therapy | ||
| Yes | 0 (0) | 0 (0) |
| No | 66 (100) | 78 (100) |
| CTx scheme | ||
| ANT | 0 (0) | 50 (64) |
| ANT-T | 0 (0) | 28 (36) |
| UNT | 66 (100) | 0 (0) |
| DFS event | ||
| Yes | 48 (73) | 29 (37) |
| Yes within 10 years | 36 (55) | 28 (36) |
| No | 18 (27) | 49 (63) |
| OS event | ||
| Yes | 37 (56) | 16 (21) |
| Yes within 10 years | 28 (42) | 14 (18) |
| No | 29 (44) | 62 (79) |
Values are presented as numbers (%). ANT, treated with anthracyclines; ANT-T, treated with anthracyclines followed by taxanes; CTx, chemotherapy; UNK, unkown; UNT, untreated (no chemotherapy).